233 related articles for article (PubMed ID: 23110993)
1. Access to regulatory data from the European Medicines Agency: the times they are a-changing.
Wieseler B; McGauran N; Kerekes MF; Kaiser T
Syst Rev; 2012 Oct; 1():50. PubMed ID: 23110993
[TBL] [Abstract][Full Text] [Related]
2. European Medicines Agency Policy 0070: an exploratory review of data utility in clinical study reports for academic research.
Ferran JM; Nevitt SJ
BMC Med Res Methodol; 2019 Nov; 19(1):204. PubMed ID: 31690260
[TBL] [Abstract][Full Text] [Related]
3. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
[TBL] [Abstract][Full Text] [Related]
4. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors.
Hodkinson A; Dietz KC; Lefebvre C; Golder S; Jones M; Doshi P; Heneghan C; Jefferson T; Boutron I; Stewart L
Syst Rev; 2018 Aug; 7(1):117. PubMed ID: 30089508
[TBL] [Abstract][Full Text] [Related]
7. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
8. Does access to clinical study reports from the European Medicines Agency reduce reporting biases? A systematic review and meta-analysis of randomized controlled trials on the effect of erythropoiesis-stimulating agents in cancer patients.
Rohner E; Grabik M; Tonia T; Jüni P; Pétavy F; Pignatti F; Bohlius J
PLoS One; 2017; 12(12):e0189309. PubMed ID: 29228059
[TBL] [Abstract][Full Text] [Related]
9. Clinical study reports published by the European Medicines Agency 2016-2018: a cross-sectional analysis.
Byrne D; Prendergast C; Fahey T; Moriarty F
BMJ Open; 2023 May; 13(5):e068981. PubMed ID: 37188475
[TBL] [Abstract][Full Text] [Related]
10. Substantial delays in clinical data published by the European Medicines Agency - a cross sectional study.
Paludan-Müller AS; Maclean-Nyegaard IR; Munkholm K
J Clin Epidemiol; 2022 Jun; 146():68-76. PubMed ID: 35292351
[TBL] [Abstract][Full Text] [Related]
11. Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status.
Boesen K; Gøtzsche PC; Ioannidis JPA
Epidemiol Psychiatr Sci; 2024 Mar; 33():e17. PubMed ID: 38529624
[TBL] [Abstract][Full Text] [Related]
12. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
13. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review.
Paludan-Müller AS; Créquit P; Boutron I
BMC Med; 2021 Apr; 19(1):88. PubMed ID: 33827569
[TBL] [Abstract][Full Text] [Related]
14. Fostering EMA's transparency policy.
Banzi R; Bertele' V; Demotes-Mainard J; Garattini S; Gluud C; Kubiak C; Ohmann C
Eur J Intern Med; 2014 Oct; 25(8):681-4. PubMed ID: 25200801
[TBL] [Abstract][Full Text] [Related]
15. Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data.
Wieseler B; Wolfram N; McGauran N; Kerekes MF; Vervölgyi V; Kohlepp P; Kamphuis M; Grouven U
PLoS Med; 2013 Oct; 10(10):e1001526. PubMed ID: 24115912
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial transparency: many gains but access to evidence for new medicines remains imperfect.
Mintzes B; Lexchin J; Quintano AS
Br Med Bull; 2015; 116():43-53. PubMed ID: 26493102
[TBL] [Abstract][Full Text] [Related]
17. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
Vinther A; Ramnarine E
PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
[TBL] [Abstract][Full Text] [Related]
18. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study.
Zeitoun JD; Lefèvre JH; Downing NS; Bergeron H; Ross JS
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):687-94. PubMed ID: 26554874
[TBL] [Abstract][Full Text] [Related]
19. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
20. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports.
Köhler M; Haag S; Biester K; Brockhaus AC; McGauran N; Grouven U; Kölsch H; Seay U; Hörn H; Moritz G; Staeck K; Wieseler B
BMJ; 2015 Feb; 350():h796. PubMed ID: 25722024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
